Cholesterol modulates LRP5 expression in the vessel wall

Atherosclerosis

Volumn 235, Issue 2, 2014, Pages 363-370

  Borrell Pages, M ^a   Romero, J C ^a   Badimon, L ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Atherosclerosis; Hypercholesterolemia; LRP5; Macrophages; Plant sterol esters; Wnt pathway

Indexed keywords

CHOLESTEROL; ESTER DERIVATIVE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; PHYTOSTEROL; PLANT STEROL ESTER; UNCLASSIFIED DRUG; WNT PROTEIN; CHOLESTEROL INTAKE; LRP5 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CONTROLLED STUDY; DIET; DISEASE COURSE; HYPERCHOLESTEROLEMIA; LIPID STORAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WNT SIGNALING PATHWAY; ANIMAL; AORTA; ATHEROSCLEROSIS; BIOSYNTHESIS; BLOOD; C57BL MOUSE; CHOLESTEROL INTAKE; DIET SUPPLEMENTATION; DRUG EFFECTS; GENETICS; HYPERLIPIDEMIAS; METABOLISM; PATHOLOGY; PHARMACOLOGY; PHYSIOLOGY; PLAQUE, ATHEROSCLEROTIC;

ANIMALS; AORTA; ATHEROSCLEROSIS; CHOLESTEROL; CHOLESTEROL, DIETARY; DIETARY SUPPLEMENTS; HYPERLIPIDEMIAS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-5; MICE, INBRED C57BL; PHYTOSTEROLS; PLAQUE, ATHEROSCLEROTIC; WNT SIGNALING PATHWAY;

EID: 84921514671     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.05.922     Document Type: Article

References (57)

1. Stancu C.S., Toma L., Sima A.V. Dual role of lipoproteins in endothelial cell dysfunction in atherosclerosis. Cell Tissue Res 2012, 349:433-446.
2. Turkish A.R., Sturley S.L. The genetics of neutral lipid biosynthesis: an evolutionary perspective. Am J Physiol Endocrinol Metab 2009, 297:E19-E27.
3. Berenson G.S., Srinivasan S.R., Bao W., Newman W.P., Tracy R.E., Wattigney W.A. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. the Bogalusa heart study. NEngl J Med 1998, 338:1650-1656.
4. Egusa G., Yamane K. Lifestyle, serum lipids and coronary artery disease: comparison of Japan with the United States. JAtheroscler Thromb 2004, 11:304-312.
5. Nissen S.E., Tuzcu E.M., Schoenhagen P., Crowe T., Sasiela W.J., Tsai J., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. NEngl J Med 2005, 352:29-38.
6. Kramsch D.M., Franzblau C., Hollander W. The protein and lipid composition of arterial elastin and its relationship to lipid accumulation in the atherosclerotic plaque. JClin Invest 1971, 50:1666-1677.
7. Suarna C., Dean R.T., May J., Stocker R. Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of alpha-tocopherol and ascorbate. Arterioscler Thromb Vasc Biol 1995, 15:1616-1624.
8. Mackness B., Hunt R., Durrington P.N., Mackness M.I. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol 1997, 17:1233-1238.
9. Lang P.D., Insull W. Lipid droplets in atherosclerotic fatty streaks of human aorta. JClin Invest 1970, 49:1479-1488.
10. Hiltunen T.P., Luoma J.S., Nikkari T., Ylä-Herttuala S. Expression of LDL receptor, VLDL receptor, LDL receptor-related protein, and scavenger receptor in rabbit atherosclerotic lesions: marked induction of scavenger receptor and VLDL receptor expression during lesion development. Circulation 1998, 97:1079-1086.
11. Llorente-Cortés V., Otero-Viñas M., Camino-López S., Costales P., Badimon L. Cholesteryl esters of aggregated LDL are internalized by selective uptake in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2006, 26:117-123.
12. Borrell-Pagès M., Romero J.C., Juan-Babot O., Badimon L. Wnt pathway activation, cell migration, and lipid uptake is regulated by low-density lipoprotein receptor-related protein 5 in human macrophages. Eur Heart J 2011, 32:2841-2850.
13. Fujino T., Asaba H., Kang M.-J., Ikeda Y., Sone H., Takada S., et al. Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. Proc Natl Acad Sci U. S. A 2003, 100:229-234.
14. Magoori K., Kang M.-J., Ito M.R., Kakuuchi H., Ioka R.X., Kamataki A., et al. Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein E. JBiol Chem 2003, 278:11331-11336.
15. Kamal-Eldin A., Moazzami A. Plant sterols and stanols as cholesterol-lowering ingredients in functional foods. Recent Pat Food Nutr Agric 2009, 1:1-14.
16. Othman R.A., Moghadasian M.H. Beyond cholesterol-lowering effects of plant sterols: clinical and experimental evidence of anti-inflammatory properties. Nutr Rev 2011, 69:371-382.
17. Weingärtner O., Ulrich C., Lütjohann D., Ismail K., Schirmer S.H., Vanmierlo T., et al. Differential effects on inhibition of cholesterol absorption by plant stanol and plant sterol esters in apoE-/- mice. Cardiovasc Res 2011, 90:484-492.
18. Rideout T.C., Harding S.V., Mackay D.S. Metabolic and genetic factors modulating subject specific LDL-C responses to plant sterol therapy. Can J Physiol Pharmacol 2012, 90:509-514.
19. Calpe-Berdiel L., Escolà-Gil J.C., Ribas V., Navarro-Sastre A., Garcés-Garcés J., Blanco-Vaca F. Changes in intestinal and liver global gene expression in response to a phytosterol-enriched diet. Atherosclerosis 2005, 181:75-85.
20. Weingärtner O., Lütjohann D., Ji S., Weisshoff N., List F., Sudhop T., et al. Vascular effects of diet supplementation with plant sterols. JAm Coll Cardiol 2008, 51:1553-1561.
21. Nashed B., Yeganeh B., HayGlass K.T., Moghadasian M.H. Antiatherogenic effects of dietary plant sterols are associated with inhibition of proinflammatory cytokine production in Apo E-KO mice. JNutr 2005, 135:2438-2444.
22. Sabeva N.S., McPhaul C.M., Li X., Cory T.J., Feola D.J., Graf G.A. Phytosterols differentially influence ABC transporter expression, cholesterol efflux and inflammatory cytokine secretion in macrophage foam cells. JNutr Biochem 2011, 22:777-783.
23. Bouic P.J., Clark A., Lamprecht J., Freestone M., Pool E.J., Liebenberg R.W., et al. The effects of B-sitosterol (BSS) and B-sitosterol glucoside (BSSG) mixture on selected immune parameters of marathon runners: inhibition of post marathon immune suppression and inflammation. Int J Sports Med 1999, 20:258-262.
24. Devaraj S., Autret B.C., Jialal I. Reduced-calorie orange juice beverage with plant sterols lowers C-reactive protein concentrations and improves the lipid profile in human volunteers. Am J Clin Nutr 2006, 84:756-761.
25. Holmen S.L., Giambernardi T.A., Zylstra C.R., Buckner-Berghuis B.D., Resau J.H., Hess J.F., et al. Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. JBone Min Res Off J Am Soc Bone Min Res 2004, 19:2033-2040.
26. Lindvall C., Evans N.C., Zylstra C.R., Li Y., Alexander C.M., Williams B.O. The Wnt signaling receptor Lrp5 is required for mammary ductal stem cell activity and Wnt1-induced tumorigenesis. JBiol Chem 2006, 281:35081-35087.
27. Cui Y., Niziolek P.J., MacDonald B.T., Zylstra C.R., Alenina N., Robinson D.R., et al. Lrp5 functions in bone to regulate bone mass. Nat Med 2011, 17:684-691.
28. Wu T., Fu J., Yang Y., Zhang L., Han J. The effects of phytosterols/stanols on blood lipid profiles: a systematic review with meta-analysis. Asia Pac J Clin Nutr 2009, 18:179-186.
29. Koh J.M., Jung M.H., Hong J.S., Park H.J., Chang J.S., Shin H.D., et al. Association between bone mineral density and LDL receptor-related protein 5 gene polymorphisms in young Korean men. JKorean Med Sci 2004, 19:407-412.
30. Urano T., Shiraki M., Usui T., Sasaki N., Ouchi Y., Inoue S. A1330V variant of the low-density lipoprotein receptor-related protein 5 (LRP5) gene decreases Wnt signaling and affects the total body bone mineral density in Japanese women. Endocr J 2009, 56:625-631.
31. Suwazono Y., Kobayashi E., Uetani M., Miura K., Morikawa Y., Ishizaki M., et al. G-protein beta 3 subunit polymorphism C1429T and low-density lipoprotein receptor-related protein 5 polymorphism A1330V are risk factors for hypercholesterolemia in Japanese males-a prospective study over 5 years. Metabolism 2006, 55:751-757.
32. Jiang X.-Y., Chen Y., Xu L., Li X., Cao F.-F., Li L., et al. Association of LPR5 polymorphism with bone mass density and cholesterol level in population of Chinese Han. Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc 2010, 118:388-391.
33. Penumathsa S.V., Thirunavukkarasu M., Koneru S., Juhasz B., Zhan L., Pant R., et al. Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. JMol Cell Cardiol 2007, 42:508-516.
34. Kim D.H., Inagaki Y., Suzuki T., Ioka R.X., Yoshioka S.Z., Magoori K., et al. Anew low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognizes apolipoprotein E. JBiochem (Tokyo) 1998, 124:1072-1076.
35. Rajamannan N.M. The role of Lrp5/6 in cardiac valve disease: experimental hypercholesterolemia in the ApoE-/-/Lrp5-/- mice. JCell Biochem 2011, 112:2987-2991.
36. Rajamannan N.M., Subramaniam M., Caira F., Stock S.R., Spelsberg T.C. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 2005, 112:I229-I234.
37. Chan K.L., Teo K., Dumesnil J.G., Ni A., Tam J. ASTRONOMER investigators. effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010, 121:306-314.
38. Hutchins P.M., Moore E.E., Murphy R.C. Electrospray MS/MS reveals extensive and nonspecific oxidation of cholesterol esters in human peripheral vascular lesions. JLipid Res 2011, 52:2070-2083.
39. Kruth H.S. Localization of unesterified cholesterol in human atherosclerotic lesions. Demonstration of filipin-positive, oil-red-O-negative particles. Am J Pathol 1984, 114:201-208.
40. Guyton J.R., Klemp K.F. Development of the atherosclerotic core region. Chemical and ultrastructural analysis of microdissected atherosclerotic lesions from human aorta. Arterioscler Thromb J Vasc Biol Am Heart Assoc 1994, 14:1305-1314.
41. Chen Z., Ichetovkin M., Kurtz M., Zycband E., Kawka D., Woods J., et al. Cholesterol in human atherosclerotic plaque is a marker for underlying disease state and plaque vulnerability. Lipids Health Dis 2010, 9:61.
42. Borrell-Pagès M., Romero J.C., Badimon L. LRP5 negatively regulates differentiation of monocytes through abrogation of Wnt signalling. JCell Mol Med 2014, 18:314-325.
43. Feingold K.R., Shigenaga J.K., Kazemi M.R., McDonald C.M., Patzek S.M., Cross A.S., et al. Mechanisms of triglyceride accumulation in activated macrophages. JLeukoc Biol 2012, 92:829-839.
44. Lopes-Virella M.F., Klein R.L., Stevenson H.C. Low density lipoprotein metabolism in human macrophages stimulated with microbial or microbial-related products. Arterioscler Dallas Tex 1987, 7:176-184.
45. Funk J.L., Feingold K.R., Moser A.H., Grunfeld C. Lipopolysaccharide stimulation of RAW 264.7 macrophages induces lipid accumulation and foam cell formation. Atherosclerosis 1993, 98:67-82.
46. Khovidhunkit W., Kim M.-S., Memon R.A., Shigenaga J.K., Moser A.H., Feingold K.R., et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. JLipid Res 2004, 45:1169-1196.
47. Martin M., Rehani K., Jope R.S., Michalek S.M. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005, 6:777-784.
48. Ahn J., Lee H., Kim S., Ha T. Curcumin-induced suppression of adipogenic differentiation is accompanied by activation of Wnt/beta-catenin signaling. Am J Physiol Cell Physiol 2010, 298:C1510-C1516.
49. Kim J., Kim J., Kim D.W., Ha Y., Ihm M.H., Kim H., et al. Wnt5a induces endothelial inflammation via beta-catenin-independent signaling. JImmunol Balt Md 1950, 2010(185):1274-1282.
50. Whyte J.L., Smith A.A., Helms J.A. Wnt signaling and injury repair. Cold Spring Harb Perspect Biol 2012, 4:a008078.
51. Rideout T.C., Harding S.V., Jones P.J.H. Consumption of plant sterols reduces plasma and hepatic triglycerides and modulates the expression of lipid regulatory genes and de novo lipogenesis in C57BL/6J mice. Mol Nutr Food Res 2010, 54(1):S7-S13.
52. Naumann E., Plat J., Kester A.D.M., Mensink R.P. The baseline serum lipoprotein profile is related to plant stanol induced changes in serum lipoprotein cholesterol and triacylglycerol concentrations. JAm Coll Nutr 2008, 27:117-126.
53. Plat J., Brufau G., Dallinga-Thie G.M., Dasselaar M., Mensink R.P. Aplant stanol yogurt drink alone or combined with a low-dose statin lowers serum triacylglycerol and non-HDL cholesterol in metabolic syndrome patients. JNutr 2009, 139:1143-1149.
54. Moghadasian M.H., McManus B.M., Pritchard P.H., Frohlich J.J. "Tall oil"-derived phytosterols reduce atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1997, 17:119-126.
55. Ntanios F.Y., van de Kooij A.J., de Deckere E.A.M., Duchateau G.S.M.J., Trautwein E.A. Effects of various amounts of dietary plant sterol esters on plasma and hepatic sterol concentration and aortic foam cell formation of cholesterol-fed hamsters. Atherosclerosis 2003, 169:41-50.
56. Plat J., Beugels I., Gijbels M.J.J., de Winther M.P.J., Mensink R.P. Plant sterol or stanol esters retard lesion formation in LDL receptor-deficient mice independent of changes in serum plant sterols. JLipid Res 2006, 47:2762-2771.
57. Weststrate J.T., Hop W.C., Aalbers A.G., Vreeling A.W., Bruining H.A. The clinical relevance of the waterlow pressure sore risk scale in the ICU. Intensive Care Med 1998, 24:815-820.